SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Class Period: Mar. 7, 2024 – May 9, 2024 Lead Plaintiff Deadline: Sept. 24, 2024 Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916-0895 Class Action Lawsuit Against MacroGenics, Inc. (MGNX): MacroGenics, Inc. shares plummeted on July 31 after the biotechnology company announced it was halting a mid-s ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Maryland on behalf of those who acquired MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) securities during the period of March 7, 2024 to May 9, 2024, inclusive ("the Class Period"). Investors have until September 24, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click here ...

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired MacroGenics, Inc. (NASDAQ: MGNX) common stock between March 7, 2024 and May 9, 2024. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. For more information, submit a form, email a ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=94047&from=3 CLASS PERIOD: March 7, 2 ...

LOS ANGELES, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ: MGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 and May 9, 2024, inclusive (the "Class Period") ...

Core Insights - MacroGenics reported a revenue of $10.8 million for Q2 2024, marking a year-over-year decline of 17.8% and an EPS of -$0.89 compared to -$0.36 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $24.14 million, resulting in a surprise of -55.28%, while the EPS surprise was -89.36% against a consensus estimate of -$0.47 [1] Revenue Breakdown - Product sales generated $5.25 million, slightly below the average estimate of $5.73 million, reflecting a year-over-year increase of 3.7% [3] - Revenue from government agreements was $0.49 million, exceeding the estimated $0.45 million, representing a year-over-year increase of 5.8% [4] - Revenue from collaborative and other agreements was $2.07 million, significantly lower than the average estimate of $8.61 million, indicating a year-over-year decline of 65.7% [5] Stock Performance - Over the past month, MacroGenics shares have returned -15.4%, compared to a -6.7% change in the Zacks S&P 500 composite [5] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [5]

MacroGenics (MGNX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.36 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -89.36%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.67 per share when it actually produced a loss of $0.84, delivering a surprise of -25.37%. Over the last four quarters, the com ...

NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MacroGenics investors who were adversely affected by alleged securities fraud between March 7, 2024 and May 9, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submi ...

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of MacroGenics, Inc. (NASDAQ: MGNX) stock or sellers of MacroGenics puts between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), have until September 24, 2024 to seek appointment as lead plaintiff of the MacroGenics class action lawsuit. Captioned Crain v. MacroGenics, Inc., No. 24-cv-02184 (D. Md.), the MacroGenics class action lawsuit charges MacroGenics as well ...

NEW YORK, Aug. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=93533&from=4 CLASS PERIOD: March 7, 2024 t ...